US neurologists are staking their hopes on gene therapy as a potential new treatment for Huntington's Disease, according to a new market report.
However, those interviewed for the report, by Spherix Global Insights, also expressed frustration at the absence of available treatments to slow cognitive decline.
Chronic pain affects approximately 60 per cent of people living with traumatic brain injury (TBI), even up to 30 years after injury, according to new research.
The study is published this month in The Journal of Head Trauma Rehabilitation (JHTR), the official journal of the Brain Injury Association of America.
Black people consistently had a higher rate of stroke than white people over a recent 22-year period, a new study shows.
The research, published in Neurology®, the medical journal of the American Academy of Neurology, also found that the average age of Black people experiencing stroke was nearly 10 years younger than that of white people, another inequity that grew over time.
Coya Therapeutics has further advanced towards clinical trials on its potential therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The company announced that it has held successful pre-IND (Investigational New Drug) and Type C meetings with the US Food and Drug Administration (FDA).
Different types of pain in multiple sclerosis (MS) can cause difficulty in staying active for some patients, new research shows.
For patients with multiple sclerosis (MS), a regular exercise routine is important for managing symptoms.
New research published in the Journal of Pain from the University of Michigan has found that widespread pain with nociplastic features, also known as WPNF, can make engaging in physical activity a painful task for some patients with MS.
Researchers have published preliminary findings on the use of cannabinoids on neuropathic pain in people with spinal cord injury.
A team of researchers at the University of Miami has explored the self-reported effects of cannabis and cannabinoids in patients with spinal cord injury.
Approximately 60% per cent of those with a spinal cord injury experience neuropathic pain, which often persists despite the use of various pharmacological treatments.
Researchers at the University of California San Diego have developed a neural implant that provides information about activity deep inside the brain while sitting on its surface.
The implant is made up of a thin, transparent and flexible polymer strip that is packed with a dense array of graphene electrodes.
The technology, tested in transgenic mice, brings the researchers a step closer to building a minimally invasive brain-computer interface (BCI) that provides high-resolution data about deep neural activity by using recordings from the brain surface.
New research has indicated that it may be possible to reduce the risk of young-onset dementia by targeting health and lifestyle factors.
Researchers at University of Exeter and Maastricht University, have identified a wide range of risk factors for young-onset dementia, challenging the notion that genetics are the sole cause of the condition and laying the groundwork for new prevention strategies.
Researchers at the University of Bristol will use wearable tech to measure symptoms of Parkinson’s Disease to determine the effectivity of a new drug or treatment in clinical trials.
The Transforming the Objective Real-world measUrement of Symptoms (TORUS) project, has received £6 million in funding from the Engineering & Physical Sciences Research Council to create the capability to monitor patients many times every day autonomously, continuously, objectively in their own home and for months at a time.
Verge Genomics, a biotechnology company using artificial intelligence (AI) to develop new treatment options, has announced the launch of a new study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS).
The study will assess the safety and tolerability of escalating doses of VRG50635, a small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, the company’s all-in-human, AI-powered platform.
